RET and non-small cell lung carcinoma: Similarly, an analysis of the phase I/II LIBRETTO-001 trial showed that selpercatinib had an objective response rate of 64% in previously treated NSCLC patients with RET fusion and 85% in patients who had not received treatment before (Subbiah et al., 2022).